Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology AG will become debt-free

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Financing
Cytos Biotechnology AG will become debt-free

04.05.2015 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.


Cytos will become debt-free.

  - Restructuring proposal final and binding to convert all bonds into

  - Settlement with loan note holders eliminates all claims from loan notes

Schlieren (Zurich), Switzerland, May 4, 2015 - Cytos Biotechnology Ltd
("Cytos") today announced that the convertible bond restructuring approved
by the superior composition authority of creditors of the canton of Zurich
("Obere Kantonale Nachlassbehörde") has become valid and binding
("rechtskräftig") and that the bonds can be converted into shares. An
extraordinary Shareholders' Meeting approved the required capital increase
already and the conversion will take place within the first half of May
2015. The incentive payment of CHF 25.00 per bond will be effected at the
same time and will be free of any withholding tax.

Further, a settlement with the convertible loan note holders was reached
eliminating all claims from the convertible loan notes immediately after
the conversion of the bonds into equity. In exchange, Cytos will make a
final payment of around CHF 4.4 million to the loan notes holders once it
has received the CHF 4 million from Novartis for the buy-out of CAD106 as
well as some payments from OnCore.

As a result of the above, Cytos will very soon be free of any debt upon
completion of the bond conversion and the settlement of the claims with the
loan note holders.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
End of ad hoc announcement

Additional features:

Document title: Cytos_Press_E_150504


04.05.2015 News transmitted by EQS Schweiz AG. - news

The issuer is responsible for the contents of the release.


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Regulated Unofficial Market in Berlin, Munich, Stuttgart;
             Open Market in Frankfurt ; SIX

End of News    EQS Group News-Service
352045 04.05.2015

Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: